The biggest problem plaguing us is the shortfall -- money we need to run the trial. In hindsight, going to existing retail holders was a big mistake. The entire capital raise should've been with institutions at .24 and we probably wouldn't be in this situation right now. Quite honestly, as holders, we have no one to blame but ourselves for this SP predicament for not taking up the full allotment and fully funding the trial.
ANP Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
